Emergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours

MT Newswires Live

Mar 04, 2025

Emergent BioSolutions (EBS) reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.

Three analysts polled by FactSet, on average, expected a $0.43 loss.

Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.

Four analysts expected $249.5 million.

For Q1, the company is projecting $200 million to $240 million in revenue.

One analyst expects $279 million.

For 2025, the company is expecting $750 million to $850 million in revenue.

Three analysts are looking for $1.11 billion.

Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516661418"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516661418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516661418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516661418","market":"hk","top_or_hot":-1,"title":"Emergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.</p><p>Three analysts polled by FactSet, on average, expected a $0.43 loss.</p><p>Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.</p><p>Four analysts expected $249.5 million.</p><p>For Q1, the company is projecting $200 million to $240 million in revenue.</p><p>One analyst expects $279 million.</p><p>For 2025, the company is expecting $750 million to $850 million in revenue.</p><p>Three analysts are looking for $1.11 billion.</p><p>Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-04 06:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emergent BioSolutions (EBS) reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.</p><p>Three analysts polled by FactSet, on average, expected a $0.43 loss.</p><p>Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.</p><p>Four analysts expected $249.5 million.</p><p>For Q1, the company is projecting $200 million to $240 million in revenue.</p><p>One analyst expects $279 million.</p><p>For 2025, the company is expecting $750 million to $850 million in revenue.</p><p>Three analysts are looking for $1.11 billion.</p><p>Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBS","symbol_name":"Emergent Biosolutions","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516661418","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516661418","pubTimestamp":1741039879,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.Three analysts polled by FactSet, on average, expected a $0.43 loss.Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.Four analysts expected $249.5 million.For Q1, the company is projecting $200 million to $240 million in revenue.One analyst expects $279 million.For 2025, the company is expecting $750 million to $850 million in revenue.Three analysts are looking for $1.11 billion.Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EBS":"Emergent Biosolutions"},"translate_title":"Emergent BioSolutions第四季度盈利下滑，收入下降——盘后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1},"content_text":"Emergent BioSolutions (EBS) reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.Three analysts polled by FactSet, on average, expected a $0.43 loss.Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.Four analysts expected $249.5 million.For Q1, the company is projecting $200 million to $240 million in revenue.One analyst expects $279 million.For 2025, the company is expecting $750 million to $850 million in revenue.Three analysts are looking for $1.11 billion.Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}